We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

PCI Biotech Holding ASA (PCIB) NOK3

Sell:1.41 NOK Buy:1.90 NOK Change: 0.018 NOK (1.08%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Sell:1.41 NOK
Buy:1.90 NOK
Change: 0.018 NOK (1.08%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Sell:1.41 NOK
Buy:1.90 NOK
Change: 0.018 NOK (1.08%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.

Contact details

Address:
Ullernchauseen 64
OSLO
0379
Norway
Telephone:
+47 (67) 115400
Website:
https://www.pcibiotech.no/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PCIB
ISIN:
NO0010405640
Market cap:
62.26 million NOK
Shares in issue:
37.33 million
Sector:
Biotechnology
Exchange:
Oslo Stock Exchange
Country:
Norway
Currency:
Norwegian Krone
Indices:
Oslo All Share Index

Key personnel

  • Hans Bohn
    Chairman of the Board
  • Ronny Skuggedal
    Chief Financial Officer
  • Anders Hogset
    Chief Scientific Officer
  • Hans Olivecrona
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.